Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma.

ABSTRACT:

Background

Primary adenosquamous carcinoma (ASC) of the lung is a rare and aggressive disease and limited information is available on the efficacy of immune checkpoint inhibitors (ICIs) for this disease. Here, we evaluated the expression status of programmed death-1 ligand 1 (PD-L1) and efficacy of ICIs in patients with pulmonary ASC.

Methods

The efficacy and toxicity of ICIs were examined in 38 patients with previously treated lung ASC from November 2017 to October 2021 in Zhejiang Cancer Hospital (Hangzhou, China). Survival curves were plotted using the Kaplan-Meier method and the Cox proportional hazards model applied for univariate and multivariate analyses.

Results

A total of 38 patients with ASC were included in this retrospective study. ICI treatment induced an

SUBMITTER: Wei J 

PROVIDER: S-EPMC9992578 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature